New combo therapy tailors radiation for advanced nasopharyngeal cancer
NCT ID NCT07248696
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This phase II trial tests a personalized treatment for metastatic nasopharyngeal carcinoma. Patients first receive tislelizumab (immunotherapy) plus chemotherapy. Those who respond well may avoid or reduce radiotherapy, while others get targeted radiation. The study aims to see if this approach improves progression-free survival with fewer side effects. It involves 32 participants and is active but not recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Tislelizumab (an immunotherapy drug) combined with gemcitabine and cisplatin chemotherapy, plus radiotherapy adjusted based on tumor response
- What this could lead to
- If successful, this approach could offer a more personalized treatment for metastatic nasopharyngeal carcinoma, potentially reducing the need for radiotherapy in patients who respond well to initial therapy.
- What could go wrong
- This is a small, early-phase trial with only 32 participants, so results may not apply to everyone. The combination therapy also carries risks of side effects from chemotherapy, immunotherapy, and radiation.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CANCINOMA (NPC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Chongqing University Cancer Hospital
Chongqing, Chongqing Municipality, 400000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a baking soda rinse tame radiation mouth sores?
- New drug duo aims to keep advanced nasopharyngeal cancer in check
- New surveillance strategy aims to catch residual cancer early in High-Risk nasopharyngeal carcinoma
- New combo strategy aims to catch and remove leftover cancer after radiation
- New combo injection targets Hard-to-Treat head and neck tumors
- New risk model may personalize Post-Chemo decisions for nasopharyngeal cancer